Here, we present a protocol that applies image-guided optoproteomics to profile the in situ proteome of endogenous EZH2-containing PRC2 bodies in the triple-negative breast cancer cell line BoM-1833. The gene discussed is EZH2; the disease is triple-negative breast carcinoma.